

TOXICOLOGICAL PROFILE FOR CADMIUM

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry

September 2012

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

UPDATE STATEMENT

A Toxicological Profile for Cadmium, Draft for Public Comment was released in September 2008. This edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology and Human Health Sciences (proposed)
Environmental Toxicology Branch (proposed)
1600 Clifton Road NE
Mailstop F-62
Atlanta, Georgia 30333

This page is intentionally blank.

FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the toxic substances each profile describes. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.


The profiles focus on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. A health effects summary describes the adequacy of information to determine a substance's health effects. ATSDR identifies data needs that are significant to protection of public health.

Each profile:

- (A) Examines, summarizes, and interprets available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) Determines whether adequate information on the health effects of each substance is available or being developed to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identifies toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are federal, state, and local health professionals; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other federal scientists also have reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Christopher J. Portier, Ph.D.
Assistant Administrator

Agency for Toxic Substances and Disease Registry

*Legislative Background

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the National Priorities List, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance's relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, and assesses the significance of toxicity data to human health.

Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length of exposure (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

Pediatrics: Four new sections have been added to each Toxicological Profile to address child health issues:

Section 1.6 **How Can (Chemical X) Affect Children?**

Section 1.7 **How Can Families Reduce the Risk of Exposure to (Chemical X)?**

Section 3.7 **Children's Susceptibility**

Section 6.6 **Exposures of Children**

Other Sections of Interest:

Section 3.8 **Biomarkers of Exposure and Effect**

Section 3.11 **Methods for Reducing Toxic Effects**

ATSDR Information Center

Phone: 1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY) **Fax:** (770) 488-4178

E-mail: cdcinfo@cdc.gov

Internet: <http://www.atsdr.cdc.gov>

The following additional material can be ordered through the ATSDR Information Center:

Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure history is provided. Other case studies of interest include *Reproductive and Developmental Hazards*; *Skin Lesions and Environmental Exposures*; *Cholinesterase-Inhibiting Pesticide Toxicity*; and numerous chemical-specific case studies.

Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. Contact: NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

Referrals

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. Contact: AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: <http://www.aoec.org/>.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. Contact: ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk Grove Village, IL 60007-1030 • Phone: 847-818-1800 • FAX: 847-818-9266.

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHOR(S):

Obaid Faroon, Ph.D. DVM
Annette Ashizawa, Ph.D.
Scott Wright, M.S.
Pam Tucker, M.D.
Kim Jenkins, B.A.
ATSDR, Division of Toxicology and Human Health Sciences (proposed), Atlanta, GA

Lisa Ingerman, Ph.D., DABT
Catherine Rudisill, B.S.
SRC Inc. (formerly known as Syracuse Research Corporation), North Syracuse, NY

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Environmental Toxicology Branch (proposed) reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.
4. Green Border Review. Green Border review assures the consistency with ATSDR policy.

This page is intentionally blank.

PEER REVIEW

A peer review panel was assembled for cadmium. The panel consisted of the following members:

1. Maryka H. Bhattacharyya, Ph.D., Senior Biochemist, Biosciences Division (BIO), Argonne National Laboratory, Lemont, Illinois 60439,
2. Masayuki Ikeda, Ph.D., M.D., Professor, Kyoto Industrial Health Association, Kyoto, Japan 604-8472, and
3. Zahir A Shaikh, Ph.D., Professor of Pharmacology and Toxicology, Director of the Center for Molecular Toxicology, University of Rhode Island, Kingston, Rhode Island 02881.

These experts collectively have knowledge of cadmium's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

This page is intentionally blank.

CONTENTS

DISCLAIMER	ii
UPDATE STATEMENT	iii
FOREWORD	v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS	vii
CONTRIBUTORS	ix
PEER REVIEW	xi
CONTENTS	xiii
LIST OF FIGURES	xvii
LIST OF TABLES	xix
1. PUBLIC HEALTH STATEMENT	1
1.1 WHAT IS CADMIUM?	2
1.2 WHAT HAPPENS TO CADMIUM WHEN IT ENTERS THE ENVIRONMENT?	2
1.3 HOW MIGHT I BE EXPOSED TO CADMIUM?	3
1.4 HOW CAN CADMIUM ENTER AND LEAVE MY BODY?	4
1.5 HOW CAN CADMIUM AFFECT MY HEALTH?	4
1.6 HOW CAN CADMIUM AFFECT CHILDREN?	5
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO CADMIUM?	6
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO CADMIUM?	7
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?	7
1.10 WHERE CAN I GET MORE INFORMATION?	8
2. RELEVANCE TO PUBLIC HEALTH	11
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO CADMIUM IN THE UNITED STATES	11
2.2 SUMMARY OF HEALTH EFFECTS	12
2.3 MINIMAL RISK LEVELS (MRLs)	15
3. HEALTH EFFECTS	45
3.1 INTRODUCTION	45
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE	45
3.2.1 Inhalation Exposure	47
3.2.1.1 Death	47
3.2.1.2 Systemic Effects	50
3.2.1.3 Immunological and Lymphoreticular Effects	94
3.2.1.4 Neurological Effects	95
3.2.1.5 Reproductive Effects	97
3.2.1.6 Developmental Effects	99
3.2.1.7 Cancer	100
3.2.2 Oral Exposure	105
3.2.2.1 Death	105
3.2.2.2 Systemic Effects	106
3.2.2.3 Immunological and Lymphoreticular Effects	169
3.2.2.4 Neurological Effects	169
3.2.2.5 Reproductive Effects	170
3.2.2.6 Developmental Effects	174
3.2.2.7 Cancer	177

3.2.3	Dermal Exposure.....	181
3.2.3.1	Death.....	181
3.2.3.2	Systemic Effects.....	181
3.2.3.3	Immunological and Lymphoreticular Effects	182
3.2.3.4	Neurological Effects.....	184
3.2.3.5	Reproductive Effects	184
3.2.3.6	Developmental Effects	184
3.2.3.7	Cancer	184
3.3	GENOTOXICITY	184
3.4	TOXICOKINETICS.....	191
3.4.1	Absorption.....	192
3.4.1.1	Inhalation Exposure	192
3.4.1.2	Oral Exposure	193
3.4.1.3	Dermal Exposure	196
3.4.2	Distribution	198
3.4.2.1	Inhalation Exposure	198
3.4.2.2	Oral Exposure	198
3.4.2.3	Dermal Exposure	200
3.4.3	Metabolism.....	200
3.4.4	Elimination and Excretion.....	200
3.4.4.1	Inhalation Exposure	201
3.4.4.2	Oral Exposure	201
3.4.4.3	Dermal Exposure	202
3.4.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	203
3.4.5.1	Summary of Cadmium PBPK Models.....	204
3.4.5.2	Cadmium PBPK Model Comparison.....	204
3.4.5.3	Discussion of Cadmium Models.....	206
3.5	MECHANISMS OF ACTION	216
3.5.1	Pharmacokinetic Mechanisms.....	216
3.5.2	Mechanisms of Toxicity.....	220
3.5.3	Animal-to-Human Extrapolations.....	223
3.6	TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS	224
3.7	CHILDREN'S SUSCEPTIBILITY	225
3.8	BIOMARKERS OF EXPOSURE AND EFFECT	230
3.8.1	Biomarkers Used to Identify or Quantify Exposure to Cadmium.....	231
3.8.2	Biomarkers Used to Characterize Effects Caused by Cadmium.....	234
3.9	INTERACTIONS WITH OTHER CHEMICALS	238
3.10	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	240
3.11	METHODS FOR REDUCING TOXIC EFFECTS.....	241
3.11.1	Reducing Peak Absorption Following Exposure.....	241
3.11.2	Reducing Body Burden	243
3.11.3	Interfering with the Mechanism of Action for Toxic Effects	244
3.12	ADEQUACY OF THE DATABASE.....	246
3.12.1	Existing Information on Health Effects of Cadmium.....	246
3.12.2	Identification of Data Needs.....	248
3.12.3	Ongoing Studies	258
4.	CHEMICAL AND PHYSICAL INFORMATION.....	261
4.1	CHEMICAL IDENTITY.....	261
4.2	PHYSICAL AND CHEMICAL PROPERTIES.....	261

5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	267
5.1 PRODUCTION	267
5.2 IMPORT/EXPORT	273
5.3 USE	273
5.4 DISPOSAL	274
6. POTENTIAL FOR HUMAN EXPOSURE	277
6.1 OVERVIEW	277
6.2 RELEASES TO THE ENVIRONMENT	281
6.2.1 Air	282
6.2.2 Water	287
6.2.3 Soil	288
6.3 ENVIRONMENTAL FATE	290
6.3.1 Transport and Partitioning	290
6.3.2 Transformation and Degradation	295
6.3.2.1 Air	295
6.3.2.2 Water	295
6.3.2.3 Sediment and Soil	295
6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	295
6.4.1 Air	296
6.4.2 Water	297
6.4.3 Sediment and Soil	298
6.4.4 Other Environmental Media	300
6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	305
6.6 EXPOSURES OF CHILDREN	319
6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	323
6.8 ADEQUACY OF THE DATABASE	324
6.8.1 Identification of Data Needs	324
6.8.2 Ongoing Studies	328
7. ANALYTICAL METHODS	333
7.1 BIOLOGICAL MATERIALS	333
7.2 ENVIRONMENTAL SAMPLES	335
7.3 ADEQUACY OF THE DATABASE	338
7.3.1 Identification of Data Needs	338
7.3.2 Ongoing Studies	342
8. REGULATIONS, ADVISORIES, AND GUIDELINES	345
9. REFERENCES	351
10. GLOSSARY	425
APPENDICES	
A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS	A-1
B. USER'S GUIDE	B-1
C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS	C-1
D. INDEX	D-1

This page is intentionally blank.

LIST OF FIGURES

2-1. Combined Chronic Oral Cadmium Intakes ($\mu\text{g}/\text{kg}/\text{day}$) and Inhalation Cadmium Exposures ($\mu\text{g}/\text{m}^3$) that Achieve a Urinary Cadmium Excretion of $0.5 \mu\text{g}/\text{g}$ Creatinine at Age 55 Years Predicted by the Cadmium Pharmacokinetic Model and the International Commission on Radiological Protection (ICRP) Human Respiratory Tract Model	24
2-2. Estimates of the UCD_{10} from Environmental Exposure Dose-Response Studies.....	40
2-3. Urinary Cadmium ($\mu\text{g}/\text{g}$ creatinine) and Renal Cortex Cadmium Concentration ($\mu\text{g}/\text{g}$ wet tissue) Predicted by the Cadmium Pharmacokinetic Model	42
3-1. Levels of Significant Exposure to Cadmium - Inhalation	69
3-2. Levels of Significant Exposure to Cadmium - Oral	131
3-3. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance.....	205
3-4. A Schematic Representation of the Nordberg-Kjellström Model.....	207
3-5. A Schematic Representation of the Shank Model	212
3-6. Existing Information on Health Effects of Cadmium.....	247
6-1. Frequency of NPL Sites with Cadmium Contamination	278
6-2. Frequency of NPL Sites with Cadmium Compounds Contamination.....	279

This page is intentionally blank.

LIST OF TABLES

2-1. Summary of Human Studies Finding Dose-Response Relationships Between Biomarkers of Renal Dysfunction and Cadmium Exposure	33
2-2. Selected Benchmark Dose Estimations of Urinary Cadmium Levels Associated with Increases in the Prevalence of Low Molecular Weight Proteinuria.....	36
2-3. Selected Studies of Dose-Response Relationship for Cadmium-Induced Low Molecular Weight Proteinuria.....	39
3-1. Levels of Significant Exposure to Cadmium - Inhalation	51
3-2. Comparison of Lung Effects Across Intermediate-Duration Inhalation Studies	78
3-3. Severity of Respiratory Effects in Rats and Mice Exposed to Cadmium Oxide for 13 Weeks.....	79
3-4. Summary of Occupational Exposure Studies Examining Renal Effects	87
3-5. Guidelines for Interpreting β 2-microglobulin Levels.....	91
3-6. Levels of Significant Exposure to Cadmium - Oral	107
3-7. Summary of Human Studies Examining Renal Effects.....	149
3-8. Benchmark Dose Estimations of Urinary Cadmium Levels ($\mu\text{g/g}$ Creatinine).....	161
3-9. Levels of Significant Exposure to Cadmium - Dermal.....	183
3-10. Genotoxicity of Cadmium <i>In Vivo</i>	185
3-11. Genotoxicity of Cadmium <i>In Vitro</i>	188
3-12. Assumed Model Parameters and Some Physiologic Parameters for the Nordberg-Kjellström Model	208
3-13. Estimated Parameters, Rate of Uptake, Rate Constants, and Biological Half-Lives in Selected Mouse Organs After Subcutaneous and Oral Administrations of $^{109}\text{CdCl}_2$	215
3-14. Ongoing Studies on Cadmium.....	259
4-1. Chemical Identity of Cadmium and Compounds	262
4-2. Physical and Chemical Properties of Cadmium and Compounds	264
5-1. Facilities that Produce, Process, or Use Cadmium	268
5-2. Facilities that Produce, Process, or Use Cadmium Compounds.....	270
6-1. Releases to the Environment from Facilities that Produce, Process, or Use Cadmium.....	283

6-2. Releases to the Environment from Facilities that Produce, Process, or Use Cadmium Compounds	285
6-3. Mean Concentrations of Cadmium for FDA’s Total Diet Study Market Baskets 2006-1 through 2008-4	302
6-4. Geometric Mean and Selected Percentile Blood Concentrations ($\mu\text{g/L}$) of Cadmium in the U.S. Population from 1999 to 2008	306
6-5. Geometric Mean and Selected Percentile Urine Concentrations (Creatinine Corrected) ($\mu\text{g/g}$ Creatinine) of Cadmium in the U.S. Population from 1999 to 2008.....	309
6-6. Geometric Mean and Selected Percentile Urine Concentrations ($\mu\text{g/L}$) of Cadmium in the U.S. Population from 1999 to 2008	312
6-7. Blood Cadmium Concentrations, Geometric Means, Adjusted Proportional Change in Means, and 95th Percentiles in New York City Adults in Population Subgroups.....	316
6-8. Occupations with Potential Exposure to Cadmium and Cadmium Compounds	318
6-9. Estimated Number of Workers Potentially Exposed to Various Chemicals in the Workplace in 1981–1983.....	320
6-10. Ongoing Studies on Cadmium.....	329
7-1. Analytical Methods for Determining Cadmium in Biological Materials	336
7-2. Analytical Methods for Determining Cadmium in Environmental Samples.....	339
7-3. Ongoing Analytical Methods Studies on Cadmium	343
8-1. Regulations, Advisories, and Guidelines Applicable to Cadmium	347